# Eysuvis (loteprednol etabonate) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/loteprednol-etabonate

> The FDA approved Eysuvis (loteprednol etabonate), sponsored by ALCON INC (ALC), on October 26, 2020.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Eysuvis (loteprednol etabonate) |
| Codes |  |
| Sponsor | ALCON INC (ALC) https://sec-api.dev/companies/alc/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### August 22, 2018: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA210565 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20180822, review_priority STANDARD; sponsor_name ALCON LABS INC; product INVELTYS (LOTEPREDNOL ETABONATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210565%22

### February 22, 2019: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208219 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20190222, review_priority STANDARD; sponsor_name BAUSCH AND LOMB INC; product LOTEMAX SM (LOTEPREDNOL ETABONATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208219%22

### August 7, 2019: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22210933_2021_Orig1s000OtherActionLtrs.pdf%22

### October 26, 2020: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA210933 ORIG-1 (Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated): submission_status AP, submission_status_date 20201026, review_priority STANDARD; sponsor_name ALCON LABS INC; product EYSUVIS (LOTEPREDNOL ETABONATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210933%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/loteprednol-etabonate.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Eysuvis (loteprednol etabonate) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/loteprednol-etabonate

```bibtex
@misc{secapidev_pdufa_loteprednol_etabonate_20261116,
  title        = {Eysuvis (loteprednol etabonate) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/loteprednol-etabonate}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_loteprednol_etabonate_20261116","title":"Eysuvis (loteprednol etabonate) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/loteprednol-etabonate","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
